case_images: PMC3747451_01
case_images: Carcinoid neuroendocrine tumor, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis.
case_images: CRIM.HEMATOLOGY2013-391086.001.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.001.jpg
case_images: fig1
case_images: The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with atrophic gastritis (Figures 1 and 2).
case_images: Carcinoid neuroendocrine tumor, stage 1, with infiltration to the subserosal layer, associated with autoimmune atrophic gastritis.
case_images: CRIM.HEMATOLOGY2013-391086.002.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.002.jpg
case_images: fig2
case_images: The pathology of the surgical specimen confirmed the initial diagnosis: carcinoid NET, stage 1, with infiltration to the subserosal layer, associated with atrophic gastritis (Figures 1 and 2).
case_images: Immunohistochemistry exam positive for chromogranin A.
case_images: CRIM.HEMATOLOGY2013-391086.003.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.003.jpg
case_images: fig3
case_images: The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
case_images: Immunohistochemistry exam positive for synaptophysin.
case_images: CRIM.HEMATOLOGY2013-391086.004.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.004.jpg
case_images: fig4
case_images: The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
case_images: Immunohistochemistry exam positive for CD56.
case_images: CRIM.HEMATOLOGY2013-391086.005.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.005.jpg
case_images: fig5
case_images: The immunohistochemistry exam tested positive for chromogranin A (Figure 3), positive for synaptophysin (Figure 4), positive for CD56 marker, (Figure 5), positive for CD8 marker and negative for CD4 marker. 
case_images: Platelet count after initiation of octreotide treatment.
case_images: CRIM.HEMATOLOGY2013-391086.006.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.006.jpg
case_images: fig6
case_images: Immediately after the first doses of octreotide, a constant increase in the platelet count was evidenced in the CBC, reaching 109,000 platelets/mm3 (Figure 6).
case_images: Platelet count after discontinuation of octreotide.
case_images: CRIM.HEMATOLOGY2013-391086.007.jpg
case_images: PMC3747451_01_CRIM.HEMATOLOGY2013-391086.007.jpg
case_images: fig7